Sarepta Therapeutics Inc (LTS:0L35)
$ 121.67 0 (0%) Market Cap: 11.61 Bil Enterprise Value: 11.80 Bil PE Ratio: 78.90 PB Ratio: 9.50 GF Score: 82/100

Sarepta Therapeutics Inc at RBC Capital Markets Global Healthcare Conference (Virtual) Transcript

May 18, 2021 / 06:30PM GMT
Release Date Price: $83.54 (+11.11%)
Brian Corey Abrahams
RBC Capital Markets, Research Division - Senior Biotechnology Analyst

Hi, good afternoon everyone. I'm Brian Abrahams, Senior Biotech Analyst at RBC Capital Markets. I'm really pleased to have with us our next presenting company, Sarepta Therapeutics, represented by their CFO, Ian Estepan. Ian, thanks for joining us.

Ian Michael Estepan
Sarepta Therapeutics, Inc. - Executive VP & CFO

Thank so much. Doug should be on his way. It seems like he's having technical difficulties, but I'm sure he'll figure it out in a little bit.

Questions & Answers

Brian Corey Abrahams
RBC Capital Markets, Research Division - Senior Biotechnology Analyst

Well, let's get started in the meantime because, obviously, a lot to cover on what's been a very exciting day. So I guess, first off, congratulations on the Study 103 results you shared this morning. What have you learned from the -- overall from the performance of the scaled up material in terms of similarity of the product to the clinical-grade

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot